HCV-TARGET
Formed in 2015, TARGET PharmaSolutions was created as an outcome of the success of HCV-TARGET, a case study of the TARGET Model for hepatitis C. HCV-TARGET was a partnership with academia, the FDA and industry established in 2011 by Michael W. Fried, MD, FAASLD and David R. Nelson, MD, which has enrolled 14,000+ patients across 60 sites in North America and Europe.
The evidence from HCV-TARGET has been utilized by regulators to monitor post-marketing drug safety, and by sponsors to support label expansion and mitigate phase IV commitments. In late 2018, Dr. Fried and members of the HCV-TARGET team received a Civilian Honor Award for Regulatory Science Excellence “For outstanding public-private partnership leveraging real-world evidence.”
The HCV-TARGET case study has helped inform national and international treatment guidelines, been used in payer dossiers, and has resulted in numerous high impact scientific presentations and publications. To date, there have been a total of 9 manuscript publications and 28 abstract presentations generated from the study. Importantly, this proven model from HCV-TARGET shaped the foundation of our TARGET PharmaSolutions company.
at a glance:
- Located in Durham, NC
- 10 Leading Pharmaceutical Company Partnerships
- 250+ Community & Academic Sites
- 7 Disease Communities
- 40+ Publications with more than 70 Unique Authors
- Key Opinion Leaders on Academic & Publication Steering Committees
Company Timeline
2011
HCV-TARGET Study
February 2015
TARGET PharmaSolutions founded
July 2016
Launched NASH community
October 2016
Launched PBC community
January 2017
Launched HCC community
July 2017
Launched IBD community
November 2017
Executed CRADA with FDA
January 2018
Site expansion in Europe
August 2018
Launched HBV community
January 2019
Launched DERM community
January 2020
New CEO Announced
March 2020
Launched ASTHMA community